TriLink's wide selection of modified nucleoside triphosphates offers researchers many novel ways to explore existing technologies typically used in drug discovery. One example is the SELEX (Systematic Evolution of Ligands by Exponential Enrichment) process of developing oligonucleotide aptamers. The SELEX process allows for the simultaneous screening of 1 x 1015 different oligonucleotides against a target of interest, such as a protein. The main goal of SELEX is to identify a small subset of aptamers from the original library that bind to the target (1). Three separate laboratories were simultaneously working on the development of this technology: Larry Gold and Craig Tuerk at the University of Colorado Boulder, Jack Szostak and Andy Ellington at Massachusetts General Hospital, and Gerald Joyce at the Scripps Institute in La Jolla, CA (2). The Colorado group was granted a patent in 1993.
The word aptamer comes from the Greek word "aptus", meaning "to fit" (3). An aptamer is an oligonucleotide ligand, generally 15-60 bases in length. It binds to the target of interest through conformational recognition, as opposed to the standard recognition mechanism for nucleic acids: hydrogen bonding of the bases to another nucleic acid strand. Oligonucleotides are often represented as linear sequences, but in reality they fold into specific conformations. It is these shapes that allow the lock-and-key fit between an aptamer and its target (4). As mentioned above, the ultimate goal of SELEX is to find an aptamer that binds to the active site of the target molecule.
Advantages of Aptamers
The SELEX Process
Gilead currently holds the patent rights to the SELEX technology and has licensed it to Archemix, who is using the technology to develop pharmaceutical applications for aptamers. Archemix has sublicensed this technology to NOXXON, who is using it for the development of their Spiegelmer® technology.
SomaLogic, a company founded by one of the original inventors, Larry Gold, has developed their own technology, called PhotoSELEX. This technology involves photoaptamers, which use a 5-Bromo-2'-deoxyuridine-5'-Triphosphate (Br-dU) (TriLink Catalog # N-2008) residue instead of a standard Thymidine. In addition to the conformational binding, there is also covalent bonding between the Br-dU residue of the aptamer and a tyrosine amino acid on the target. The Br-dU oligonucleotides are exposed to radiation and those that are in the correct conformation will covalently crosslink to specific sites on the target molecule. Those that do not crosslink are washed away, while those that remain are amplified by PCR. These photoaptamers are put into arrays so that large numbers of proteins can be tested at the same time (4).
SELEX is just one of many applications that modified nucleoside triphosphates can be used in. TriLink offers a wide variety of modified nucleoside triphosphates that can be used for research purposes.
SELEX is patented by Gilead.
PhotoSELEX is patented by SomaLogic, Inc.
Spiegelmer® is a registered trademark of NOXXON Pharma AG.
Certain nucleoside triphosphates are sold by TriLink under licenses that provide limited rights to end users for research purposes. The purchase of a compound from TriLink does not convey rights for use in any particular application. TriLink makes no representations or warranties that the use of any compound, alone or in combination with other products, or in any process, will not infringe the claims of a United States or foreign patent.